Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
OKUWA's FY02/26 Results Fall Short of Guidance
OKUWA CO., LTD. <8217> announced after the close of trading that its consolidated results for the fiscal year ending February 2026, currently being compiled, are expected to fall short of previous guidance. Sales are now projected at \252.6 billion (up 1.0% year-on-year), down from the previous forecast of \259.0 billion. Operating profit is expected to reach \1.87 billion (up 40.8% year-on-year), down from the prior guidance of \2.1 billion. Net profit is projected at \260 million, compared to the previous forecast of \800 million and a net loss of \2.381 billion in the prior fiscal year.
The company attributed the shortfall to intensifying competition across retail formats and the further polarization of consumer spending due to rising prices, which prevented OKUWA from achieving its planned customer traffic targets. Additionally, impairment losses on stores with declining profitability weighed on net profit.
Source: MINKABU PRESS
Related Articles
Saikaya Department Store rebounds after 6-day decline on stronger-than-expected interim results amid gold price surge
TAIYO HOLDINGS shares fall sharply for fifth straight day as KKR launches tender offer at \4,750 per share for privatization
FX Summary: Yen strengthens to 158.40 range on buying triggered by BOJ Tankan survey
NIPPON FELT surges to daily limit on first rebound in 6 days after DOE 5 Percent acquires over 5% stake
SONY GROUP Surges on Strategic Partnership with TCL in Home Entertainment
AI-Driven Programs Ignite Volatile Market: Key Points for Tomorrow's Trading
LIFEDRINK COMPANY falls for first time in 5 days as profit-taking outweighs Iris Ohyama's consecutive stake increase reports
CHUGAI PHARMA extends gains as U.S. FDA approves Eli Lilly's oral obesity drug Founayo
Vitabrid Japan debuts at \1,301, 5.0% below IPO price
QPS HD, Astroscale HD and other space development-related stocks surge on successful Artemis launch attracting investment flowsâ—‡